Drugs / U29
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07453446 | Mar 2025 → Mar 2027 | lymphoma | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | U29 | “Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma” NCT07453446 ↗ |
| Known as | CD30 CAR-T Cells | “U29(CD30 CAR-T Cells)” NCT07453446 ↗ |
| Known as | CD30-CART | “Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma” NCT07453446 ↗ |